Ergot mesylates for alzheimer's disease: A year‐long double‐blind trial of 3 mg vs 12 mg daily

Michael A. Jenike, Marilyn Albert, Lee Baer, Jeanette Gunther, Christine Corvino

Research output: Contribution to journalArticle

Abstract

Of 25 patients who entered a year‐long double‐blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylates (Hydergine), 17 completed the full year of study and no patients suffered problematic side‐effects. On a number of complex tests of memory function, there was no difference between the patients receiving low‐dose versus high‐dose Hydergine. There were also no significant between‐group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.

Original languageEnglish (US)
Pages (from-to)375-380
Number of pages6
JournalInternational journal of geriatric psychiatry
Volume5
Issue number6
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Keywords

  • Alzheimer's disease
  • Hydergine
  • dementia
  • ergot mesylates

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Ergot mesylates for alzheimer's disease: A year‐long double‐blind trial of 3 mg vs 12 mg daily'. Together they form a unique fingerprint.

  • Cite this